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Aim of this study was to analyse the association between the use of diagnostic ureteroscopy (URS) and the development of intravesical recurrence (IVR) in patients undergoing radical nephroureterectomy (RNU) for high-risk upper tract urothelial carcinoma. A systematic review of the published data was performed up to December 2016, using multiple search engines to identify eligible studies. A formal meta-analysis was conducted of studies comparing patients who underwent URS before RNU with those who did not. Hazard ratios (HRs), with their 95% confidence intervals (CIs), from each study were used to calculate pooled HRs. Pooled estimates were calculated using a fixedeffects or random-effects model according to heterogeneity. Statistical analyses were performed using REVMAN, version 5. Seven studies were included in the systematic review, but only six of these were deemed fully eligible for metaanalysis. Among the 2 382 patients included in the metaanalysis, 765 underwent diagnostic URS prior to RNU. All examined studies were retrospective, and the majority examined Asian populations. The IVR rate ranged from 39.2% to 60.7% and from 16.7% to 46% in patients with and without prior URS, respectively. In the pooled analysis, a statistically significant association was found between performance of URS prior to RNU and IVR (HR 1.56, 95% CI 1.33-1.88; P < 0.001). There was no heterogeneity in the observed outcomes, according to the I 2 statistic of 2% (P = 0.40). Within the intrinsic limitations of this type of analysis, these findings suggest a significant association between the use of diagnostic URS and higher risk of developing IVR after RNU. Further research in this area should be encouraged to further investigate the possible causality behind this association and it potential clinical implications.
Introduction
Upper tract urothelial carcinoma (UTUC) represents a relatively rare disease [1, 2] , which can, however, have a significant clinical impact. Indeed,~60% of UTUCs are invasive at diagnosis, compared with 15-25% of bladder urothelial cancers [3] . A combination of laboratory, imaging and endoscopic methods is used for diagnosis and risk stratification of UTUC [4] . CT urogram is used, alone or in combination with other tools, to detect and stage UTUC, albeit with a misdiagnosis rate of up to 15.5%. The introduction of ureteroscopy (URS) brought about a reduction in the misdiagnosis rate to 2.1%, secondary to the possibility of visually exploring the entire upper urinary tract [4] . In addition, information obtained during URS can help in risk stratification of UTUC [3, 4] ; however, concerns have been raised about the possibility of tumour seeding secondary to the ureteroscopic manipulation of the UTUC, with a consequently higher risk of intravesical recurrence (IVR) [5] .
Radical nephroureterectomy (RNU) is the standard treatment for high-risk UTUC. In addition to its loco-regional and distant recurrence rate, it is associated with a 22-47% risk of IVR [6, 7] . Two recent meta-analyses investigated the main risk factors associated with IVR, including patient-, tumourand treatment-specific factors [7, 8] . Nevertheless, both metaanalyses lacked an investigation of the impact of URS on IVR after RNU, which remains controversial.
The aim of the present study was to summarize and analyse the current data regarding the impact of diagnostic/staging URS on the development of IVR in patients undergoing RNU for UTUC.
Materials and Methods

Search Strategy
A computerized bibliographic search was conducted by two authors (M.M., G.P.) in December 2016 to identify studies reporting the incidence of IVR in patients with UTUC undergoing diagnostic URS prior to RNU. PubMed, Ovid and Scopus were used as search engines. Different combinations of the following search terms were used according to a freetext protocol: 'ureteroscopy', 'urothelial cancer', 'transitional cell carcinoma', 'upper urinary tract cancer', 'intravesical recurrence' and 'ureterorenoscopy'. Reference lists of the retrieved articles were also used to identify any other relevant study. For the Medline search, we used the following filters: languages (English); species (humans); and text availability (full-text availability). No filters were applied for the date of publication.
Selection of Studies
In order to define study eligibility according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) criteria (www.prisma-statement.org) [9] , we used the PICO (Population, Intervention, Comparator, Outcome) study design approach. Studies were deemed eligible if they compared patients with UTUC (P) who underwent diagnostic URS before RNU (I) with those who did not undergo URS (C) to determine the risk of IVR (O).
Titles of articles were first reviewed to determine whether they might potentially fit the inclusion criteria. After assessing the abstract, the full-text articles underwent a more exhaustive assessment. Studies without primary data (i.e. reviews, commentaries and letters) were also excluded, but they were examined to include any possible relevant citations.
Conference abstracts were not considered to be methodologically appropriate. Only studies providing hazard ratios (HRs) from multivariate analysis with their corresponding 95% CIs were retained. Disagreement on whether or not an article should be included was resolved using a third reviewer (R.A.).
Data Extraction
For each selected study, the following items were recorded: first author's name, year of publication, study design, country of origin, study period, patients' characteristics (number, age, and gender), tumour characteristics (stage, grade, size), diagnostic and surgical management, IVR rate and follow-up duration.
Assessment of Study Quality
The quality of the study was determined using the Newcastle-Ottawa Scale for cohort studies [10] . A total score of ≤5 was considered low-, a score of 6 was considered intermediate-, and scores of 7-9 were considered high-quality.
Data Analysis
All statistical analyses were performed using REVMAN 5 (Cochrane Collaboration, Oxford, UK). HRs with their 95% CIs from each study were used to calculate pooled HRs. Pooled estimates were calculated by using a random-effect model. To evaluate publication bias, Egger linear regression and funnel plots were examined.
Results
The study selection flow chart according to the PRISMA statement is shown in Fig. 1 . A total of 37 studies were included for final evaluation, of which only seven were included in the systematic review [5, [11] [12] [13] [14] [15] [16] , but only six were deemed fully eligible for meta-analysis; the study by Ishikawa et al. [11] could not be included because of the lack of HR value at multivariate analysis. Tables 1 and 2 [5, [11] [12] [13] [14] [15] [16] show the main characteristics and findings of the included studies. Among the 2 372 patients included in the meta-analysis, 765 underwent diagnostic URS prior to RNU. All examined studies were retrospective, and the majority examined Asian populations. The IVR rate ranged from 39.2% to 60.7% and from 16.7% to 46% in patients with and without prior URS, respectively. At pooled analysis, a statistically significant association was found between performance of URS prior to RNU and IVR (HR 1.56, 95% CI 1.33-1.88; P < 0.001). There was no heterogeneity in the observed outcomes according to the I 2 statistic of 2% (P = 0.40; Fig. 2) . The overall quality was high, with only one study of intermediate quality [16] . Visual inspection of funnel plots showed no obvious publication bias. 
Discussion
Presence of carcinoma in situ, multifocality, tumour location and grade have been previously recognized as risk factors for IVR [17, 18] . The impact of diagnostic URS on IVR has not been well defined to date, which prompted us to perform the present analysis. We hypothesized that the use of diagnostic URS prior to RNU might be associated with a higher risk of IVR, and we found that, indeed, in patients who had diagnostic URS the likelihood of IVR was increased by~50%.
The use of high intrapelvic pressure during URS, with subsequent pyelolymphatic and pyelovenous backflow, has been regarded as a potential cause of tumour seeding [19] . This has led several groups to investigate the oncological safety of diagnostic URS. In an early small series of patients who underwent diagnostic URS before RNU, Kulp and Bagely [20] found no evidence of tumour cells in the vascular and lymphatic spaces of the specimen. In addition, Hendin et al. [21] found no significant difference in disease-specific survival of patients who underwent diagnostic URS before RNU compared with those who did not [21] . Similar findings were later reported by others [22, 23] . More recently, in a larger analysis including >500 patients from 21 French centres, Nison et al. [24] confirmed that URS does not impact extravesical recurrence or survival in patients with UTUC.
These studies were also aimed at answering the question of whether delaying the RNU to perform a diagnostic URS (in addition to the high pressure and instrumentation of the ureter itself) would translate into worse oncological outcomes, as previous evidence had shown that delaying radical cystectomy in patients with urothelial bladder cancer translated into worse survival rates [25] .
Ishikawa et al. [11] were among the first to look specifically at the impact of pre-RNU URS, not only on cancer-specific survival but also on IVR. In an analysis of 208 cases, they found that only 55 patients (26.5%) had undergone a diagnostic URS. No difference was found in terms of IVR, with patients bladder recurrence-free survival at 2 years being 60% in the URS group and 58.7% in the non-URS group (P = 0.97). These authors concluded that URS does not adversely affect IVR in patients undergoing RNU. Different conclusions were drawn by Luo et al. [12] , who studied a larger sample (396 patients). Diagnostic URS (which in that study occurred either within a week or on the same day as RNU) was associated with increased IVR in both patients CSM, cancer-specific mortality; CSS, cancer-specific survival; IVR, intravesical recurrence; MFS, metastasis-free survival; MIS, minimally invasive surgery (laoaroscopic or robotic); nr, not reported; OS, overall survival; PFS, progression-free survival; RFS, recurrence-free survival; RNU, radical nephroureterectomy; URS, ureteroscopy. IVR, intravesical recurrence; URS, ureteroscopy. *The total cohort was divided into three groups, depending on the timing of URS: the no-URS group, which included 30 patients who did not undergo diagnostic URS; the one-session group, which included 33 patients who had undergone diagnostic URS and then immediately underwent RNU on same day; and the two-session group, which included 41 patients who had undergone diagnostic URS followed later (median 5 days) by RNU. † IVR rate was calculated excluding patients with prior bladder tumour history. IVR rates were obtained from IVR free-survival when reported in the original papers.
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© 2017 The Authors BJU International © 2017 BJU International with and without history of bladder cancer (P = 0.02 and P = 0.016, respectively). This was also confirmed on multivariable analysis where history of bladder cancer, URS and multiple tumours were found to be significant independent risk factors for IVR.
Subsequent studies confirmed the negative impact of URS on the development of IVR. Sung et al. [5] retrospectively analysed 630 patients, of whom 44.7% had received diagnostic URS. The median time from URS to RNU was 16 days, and IVR developed in 42.5% of cases. The 5-year IVR-free survival rates were 42.6% and 63.6% in patients with and without URS (P < 0.001), respectively. On multivariable analysis, history of bladder cancer, extravesical excision of distal ureter, tumour multifocality, and occurrence of URS were independent predictors of higher IVR [5] . Interestingly, these authors also found that shortening the interval from URS to RNU or performing URS without manipulation (biopsy) did not reduce the IVR rate. Lee et al. [13] focused on the time between URS and RNU as a possible significant factor. They analysed 104 cases, which were divided into those who did not receive URS, those who underwent URS and RNU in the same surgical session, and those who first underwent URS and then RNU. IVR was recorded in 33.3% of cases. On multivariable analysis, the two-session approach was an independent risk factor for increased IVR (HR 3.61). The authors speculated that this finding could be explained by a combination of causes, including seeding of tumour cells favoured by inflammation of the urothelium secondary to URS.
Yoo et al. [14] hypothesized that the impact of URS biopsy on IVR might be influenced by tumour location. To assess this, they studied 387 patients, of whom 17.8% underwent a URS biopsy prior to RNU. IVR occurred in 41.1% of cases and the postoperative 5-year IVR-free survival was 51.4%. URS biopsy was an independent risk factor for IVR only in patients with renal pelvic tumours (HR 1.98, P = 0.02), and not in those with a ureteric tumour location. An explanation for this finding could be that tumour cells have probably already shed into the bladder from the ureter, making the further spreading caused by URS unlikely to have a significant impact on IVR. By contrast, endoscopic manipulation of tumours located in the renal pelvis might offset the 'protective' distance between these tumours and the bladder, thus increasing the risk of IVR.
Several limitations of the present analysis should be considered, including the retrospective design of included studies, and the lack of details regarding the ureteroscopic technique (semi-rigid vs flexible) as well as the RNU technique. For example, it has been recognized that the management of the distal ureter and bladder cuff during RNU can have an impact on oncological outcomes [26] . Moreover, causal factors that may lead to higher IVR in patients undergoing URS could not be identified, and they remain purely speculative. Other factors, such as having a ureteric stent placed after URS or the operative length of the URS procedure, might potentially have an impact on the IVR rate, but this also remains to be determined. The length of time between diagnostic URS and subsequent RNU was only specified in four of the studies included in the present analysis [5, 12, 14] , varying between 1 and 3 weeks overall. It was not possible to specifically perform a cumulative analysis of the impact of this variable, and this could be an additional issue to further explore. Lee et al. [13] were the only authors to focus specifically on the timing of RNU after URS. Interestingly, that study showed that the IVR rate in the onesession group (in which patients underwent RNU immediately after URS) was similar to the IVR rate in the no-URS group, whereas both of these groups had statistically fewer occurrences of IVR than the two-session group. The authors concluded, therefore, that URS should preferably be performed at the time of RNU.
Notwithstanding these limitations, the importance of the present results should be regarded in the light of the progressive increase in the use of diagnostic and staging URS. The augmented risk of IVR could lead to a worse quality of life as a result of continuous cystoscopy follow-up, the necessity for tumour resection and the development of muscle-invasive bladder cancer [3, 27] . It seems reasonable, therefore, to limit diagnostic URS to patients who could benefit from its performance with regard to treatment decision. Furthermore, the use of prophylactic intravesical instillation after RNU should be tested to assess whether it reduces the risk of IVR after URS as it does after RNU. Ultimately, the identification of patients at risk of IVR may assist in determining the best management for them [18] . Overall, much remains to be studied in this field, and further prospective controlled studies are needed to set a personalized safe and effective strategy.
In conclusion, notwithstanding the limitations of this type of analysis, there seems to be a significant association between the use of diagnostic URS and increased risk of IVR after RNU in patients with UTUC. Despite not translating into worse metastasis or survival outcomes, the higher likelihood of IVR can have a significant negative impact on patients' quality of life. These findings suggest that urologists should use diagnostic URS on a selective basis only, where its use may alter clinical decision-making. Further research is this area is warranted to investigate the possible causality behind this association, and its clinical implications.
